Search | Clinical Trials Finder

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Wound Heal
Interventions: Timolol 0.25% Ophthalmic Solution, Standard Wound Care; Drug · Other
Lead sponsor: Keith G. LeBlanc, Jr, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Trabodenoson, Latanoprost, Timolol; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bristol, Tennessee

Conditions: Open Angle Glaucoma (OAG), Glaucoma
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Glaucoma
Interventions: bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension, Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension, Timolol 5 mg/ml eye drops, solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 15
States / cities: New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Artesia, California • Petaluma, California • Morrow, Georgia + 1 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: timolol hemihydrate, timolol maleate; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Glaucoma
Interventions: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Glendale, California • Newport Beach, California • Pasadena, California + 11 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Normal Tension Glaucoma (NTG)
Interventions: QLS-101, Timolol maleate PF 0.5% ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Slingerlands, New York

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Migraine
Interventions: Timolol, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Topical Timolol: a Comparison of Surgical Outcomes

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

AR-12286 in Combination With Latanoprost

SYL040012, Treatment for Open Angle Glaucoma

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine